Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Analytic aspects of cyclosporine monitoring, on behalf of the IFCC/IATDMCT joint working group|
|Citation:||Therapeutic Drug Monitoring, 2004; 26(2):227-230|
|Publisher:||Lippincott Williams & Wilkins|
|Raymond G. Morris, David W. Holt, Victor W. Armstrong, Andrea Griesmacher, Kimberly L. Napoli, and Leslie M. Shaw|
|Abstract:||The use of therapeutic drug monitoring strategies for cyclosporin (CsA) has evolved markedly in recent years since previous consensus guidelines were presented. Apart from the introduction of some new methods, the major change has been the shift away from the traditional predose/trough (C0) sample. The most popular alternative has been shown to be a 2-hour postdose (C2) sample. This has presented a challenge to clinical laboratories where typical C2 sample concentrations exceed the upper limit of the calibration range for their chosen CsA method, hence requiring an accurate dilution to be performed. Data from the Australian/New Zealand survey, as well as that in the International CsA Proficiency Testing Program, have demonstrated both a plethora of dilution protocols and resultant widespread failure of many laboratories to obtain accurate results. This paper compares data from several independent sources, pointing to international problems for reliable CsA measurement in clinical laboratories. This includes the CsA method selection criteria adopted by a large percentage of laboratories in various surveys, indicating that the least specific mFPIA methods have been widely adopted.|
|Keywords:||cyclosporin; therapeutic drug monitoring; immunoassay|
|Rights:||© 2004 Lippincott Williams & Wilkins|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.